DNA methyltransferase (DNMT) inhibitors azacitidine and decitabine, antimetabolites that can inhibit DNMT activity and induce hypomethylation when incorporated into DNA, have been approved to treat myelodysplastic syndrome or leukemia [22, 23]. The gene discussed is DNMT1; the disease is myelodysplastic syndrome.